Whole-genome sequencing identifies ADGRG6 enhancer mutations and FRS2 duplications as angiogenesis-related drivers in bladder cancer

Song Wu (), Tong Ou, Nianzeng Xing, Jiang Lu, Shengqing Wan, Changxi Wang, Xi Zhang, Feiya Yang, Yi Huang and Zhiming Cai
Additional contact information
Song Wu: Urology Institute of Shenzhen University, The Third Affiliated Hospital of Shenzhen University, Shenzhen University
Tong Ou: Urology Institute of Shenzhen University, The Third Affiliated Hospital of Shenzhen University, Shenzhen University
Nianzeng Xing: Capital Medical University
Jiang Lu: Urology Institute of Shenzhen University, The Third Affiliated Hospital of Shenzhen University, Shenzhen University
Shengqing Wan: Shenzhen Following Precision Medical Research Institute, Luohu Hospital Group
Changxi Wang: Urology Institute of Shenzhen University, The Third Affiliated Hospital of Shenzhen University, Shenzhen University
Xi Zhang: Urology Institute of Shenzhen University, The Third Affiliated Hospital of Shenzhen University, Shenzhen University
Feiya Yang: Capital Medical University
Yi Huang: Urology Institute of Shenzhen University, The Third Affiliated Hospital of Shenzhen University, Shenzhen University
Zhiming Cai: Urology Institute of Shenzhen University, The Third Affiliated Hospital of Shenzhen University, Shenzhen University

Nature Communications, 2019, vol. 10, issue 1, 1-12

Abstract: Abstract Bladder cancer is one of the most common and highly vascularized cancers. To better understand its genomic structure and underlying etiology, we conduct whole-genome and targeted sequencing in urothelial bladder carcinomas (UBCs, the most common type of bladder cancer). Recurrent mutations in noncoding regions affecting gene regulatory elements and structural variations (SVs) leading to gene disruptions are prevalent. Notably, we find recurrent ADGRG6 enhancer mutations and FRS2 duplications which are associated with higher protein expression in the tumor and poor prognosis. Functional assays demonstrate that depletion of ADGRG6 or FRS2 expression in UBC cells compromise their abilities to recruit endothelial cells and induce tube formation. Moreover, pathway assessment reveals recurrent alterations in multiple angiogenesis-related genes. These results illustrate a multidimensional genomic landscape that highlights noncoding mutations and SVs in UBC tumorigenesis, and suggest ADGRG6 and FRS2 as novel pathological angiogenesis regulators that would facilitate vascular-targeted therapies for UBC.

Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-019-08576-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-08576-5

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-019-08576-5

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().